NAD(P)H：醌氧化还原酶1（NQO1）C609T基因多态性与日本人患八种癌症的风险

NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese.

作者信息

Hamajima Nobuyuki, Matsuo Keitaro, Iwata Hiroji, Shinoda Masayuki, Yamamura Yoshitaka, Kato Tomoyuki, Hatooka Shunzo, Mitsudomi Tetsuya, Suyama Motokazu, Kagami Yoshitoyo, Ogura Michinori, Ando Manabu, Sugimura Yoshiki, Tajima Kazuo

机构信息

Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan.

出版信息

Int J Clin Oncol. 2002 Apr;7(2):103-8. doi: 10.1007/s101470200013.

DOI:10.1007/s101470200013

PMID:12018106

Abstract

BACKGROUND

NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T was reportedly associated with leukemia, lung cancer, colorectal cancer, and urological malignancies. This study was conducted to screen possible cancer sites associated with this polymorphism by a prevalent case-control design.

METHODS

The cases were 102 patients with esophageal cancer, 143 with stomach cancer, 74 with colon cancer, 72 with rectal cancer, 192 with lung cancer, 237 with breast cancer, 56 with prostate cancer, and 108 with malignant lymphoma. Controls consisted of outpatients from two sources: 241 noncancer outpatients who underwent gastroscopy and 399 first-visit outpatients, expected to include about 20% with cancer. Genotyping was conducted by polymerase chain reaction with confronting two-pair primers (PCR-CTPP).

RESULTS

The TT genotype with null enzyme activity was found in 19.9% of the 241 noncancer gastroscopy examinees, 16.5% of the 399 first-visit outpatients, 12.7% of the esophageal cancer patients, 16.8% of the stomach cancer patients, 13.5% of the colon cancer patients, 9.7% of the rectal cancer patients, 17.7% of the lung cancer patients, 14.3% of the breast cancer patients, 16.1% of the prostate cancer patients, and 15.7% of the malignant lymphoma patients. The odds ratios (ORs) of the genotypes were not significant for any cancers combined or for any site of cancer, except for lung cancer (OR, 0.66; 95% confidence interval [CI], 0.46-0.96 for CT relative to CC). The OR of current smoking for cancers of the esophagus and lung combined was different between the CC genotype (OR, 2.06; 95% CI, 1.06-3.98) and TT genotype (OR, 5.11; 95% CI, 1.37-19.05), although the difference was not significant.

CONCLUSION

This study suggests that the CC genotype of the NQO1 C609T polymorphism is associated with the risk of lung cancer, and that the TT genotype increases the risk of smoking for cancers of the esophagus and lung.

摘要

背景

据报道，NAD(P)H：醌氧化还原酶1（NQO1）C609T与白血病、肺癌、结直肠癌和泌尿系统恶性肿瘤有关。本研究采用现患病例对照设计，以筛查与该多态性相关的可能癌症部位。

方法

病例包括102例食管癌患者、143例胃癌患者、74例结肠癌患者、72例直肠癌患者、192例肺癌患者、237例乳腺癌患者、56例前列腺癌患者和108例恶性淋巴瘤患者。对照组由两个来源的门诊患者组成：241例接受胃镜检查的非癌症门诊患者和399例初诊门诊患者，预计其中约20%患有癌症。采用两对引物直接测序法聚合酶链反应（PCR-CTPP）进行基因分型。

结果

在241例接受胃镜检查的非癌症患者中，19.9%发现具有无酶活性的TT基因型；在399例初诊门诊患者中，16.5%发现该基因型；在食管癌患者中，12.7%发现该基因型；在胃癌患者中，16.8%发现该基因型；在结肠癌患者中，13.5%发现该基因型；在直肠癌患者中，9.7%发现该基因型；在肺癌患者中，17.7%发现该基因型；在乳腺癌患者中，14.3%发现该基因型；在前列腺癌患者中，16.1%发现该基因型；在恶性淋巴瘤患者中，15.7%发现该基因型。除肺癌外（CT相对于CC的比值比[OR]为0.66；95%置信区间[CI]为0.46 - 0.96），该基因型的比值比在合并的任何癌症或任何癌症部位均无统计学意义。食管和肺癌合并时，CC基因型（OR为2.06；95%CI为1.06 - 3.98）和TT基因型（OR为5.11；95%CI为1.37 - 19.05）的当前吸烟OR不同，尽管差异无统计学意义。